Novo Nordisk Rebrands Rybelsus as Ozempic Pills to Strengthen US Position
New Delhi: Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world's best-selling drugs.
The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.
Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name Rybelsus, which have the same main ingredient, semaglutide, but in a different formulation and set of doses. Rybelsus will continue to be marketed outside the US.
Novo is trying to win back market share from rival Eli Lilly & Co., pinning its comeback on new formulations of its top-selling medicines and a more direct-to-consumer approach.
A Wegovy pill introduced in January has had the strongest launch of any obesity drug to date, while Novo has also introduced a subscription program offering lower monthly prices for the drug.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.